WHY IT MATTERS: As federal rescheduling moves forward, organizations that center both clinical evidence and patient experience could directly shape whether patients gain broader, safer, and more affordable access to cannabinoid therapies. CLINICAL OVERVIEW: A newly formed cannabis medicine group is working to ensure that federal policy discussions around cannabinoid therapy are rooted in scientific evidence and shaped by real patient perspectives. This effort comes at a critical moment as rescheduling conversations advance at the federal level, creating an opening to influence how cannabis is regulated, researched, and integrated into clinical care.
Bill to protect Nebraska physicians recommending medical cannabis advances to floor
WHY IT MATTERS: If this bill passes, Nebraska patients will have a much better chance of finding a licensed physician willing to openly discuss and recommend medical cannabis without fear of losing their medical license. CLINICAL OVERVIEW: Physician protection legislation in Nebraska addresses a longstanding barrier to medical cannabis access: the fear among doctors that recommending cannabis could expose them to professional or legal consequences under state licensing boards. Without such protections, many qualified physicians avoid cannabis consultations entirely, leaving patients without informed medical guidance even in states where the therapy is legal.